Dawnielle Endly, DO
Dermatology · Aurora, CONPI 1568807238
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $89,375 of the $104,566 with a category attached, or 85.5%. AbbVie accounts for 94.0% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $43,476, more than ten times the $1,489 reported in 2019. Among dermatology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 472 payments — averaging $221.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$98K
- Lilly USA, LLC$761
- E.r. Squibb & Sons, L.L.C.$702
- EPI Health, LLC$646
- Johnson & Johnson$473
- Novartis$437
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$89,37585%
- Travel & lodging$6,0826%
- Food & beverage$9,0049%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 213 | $98,248 |
| Lilly USA, LLC | 29 | $761 |
| E.r. Squibb & Sons, L.L.C. | 34 | $702 |
| EPI Health, LLC | 4 | $646 |
| Johnson & Johnson | 20 | $473 |
| Novartis | 20 | $437 |
| Sanofi | 13 | $419 |
| Amgen | 14 | $397 |
| Sun Pharmaceutical Industries Inc. | 20 | $384 |
| UCB, Inc. | 18 | $364 |
| Regeneron Healthcare Solutions, Inc. | 13 | $314 |
| Pfizer | 17 | $285 |
| Organon | 6 | $177 |
| Incyte Corporation | 10 | $154 |
| LEO Pharma Inc. | 7 | $129 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $102 |
| Galderma Laboratories, L.p. | 5 | $97 |
| Arcutis Biotherapeutics, Inc. | 5 | $83 |
| Dermira, Inc. | 5 | $81 |
| Strata Skin Sciences, Inc. | 1 | $77 |
| Almirall LLC | 4 | $66 |
| Dermavant Sciences, Inc. | 2 | $35 |
| VYNE Pharmaceuticals Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| DUSA Pharmaceuticals, Inc. | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$85,327
- Sitavig$625
- Cloderm$625
- Minolira 105mg$625
- Minolira 135mg$625
- Rhofade$625
- VTAMA$146
- Enbrel$122
- OLUMIANT$121
- Skyrizi$114
How this compares
$104,566 in reported general payments places this provider in the 95th percentile of 280 dermatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 37 | $152,084 |
| RinvoqUpadacitinib | 13 | $86,114 |
| Clobetasol Propionate | 84 | $3,403 |
| Ketoconazole | 106 | $1,642 |
| Fluocinonide | 35 | $1,361 |
| Fluorouracil | 19 | $1,213 |
| Doxycycline Hyclate | 19 | $750 |
| Triamcinolone Acetonide | 85 | $722 |
| Tretinoin | 14 | $616 |
| Hydrocortisone | 44 | $528 |
| Hydroxyzine Hcl | 18 | $362 |
| ValacyclovirValacyclovir Hcl | 21 | $294 |
| Mupirocin | 31 | $271 |
| Minoxidil | 16 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $98,248 | $86,11413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 dermatology providers in Colorado.
Other dermatology in Aurora
- David NorrisAurora$156K
- Torunn SivesindAurora$93K
- Carla Torres-ZegarraAurora$62K
- Cory DunnickAurora$39K
- Theodore AlkousakisAurora$34K
- Emily GorellAurora$27K
- Ryan GambleAurora$10K
- Jennifer RayAurora$9K
- Ryan OlearyAurora$8K
- Marcjonathan SerotaLittleton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.